Effect of Intestinal Flora on Hyperuricemia-Induced Chronic Kidney Injury in Type 2 Diabetic Patients and the Therapeutic Mechanism of New Anti-Diabetic Prescription Medications

References

• Lin S. Interpretation of Chinese guidelines for the diagnosis and treatment of hyperuricemia and gout (2019). J Clin Med. 2020;37(06):460–462.
   Google Scholar
• Bartakova V, Kuricova K, Pacal L, et al. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus. J Diabetes Complications. 2016;30(7):1300–1307. doi:10.1016/j.jdiacomp.2016.06.002
   PubMed Web of Science ®Google Scholar
• Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. doi:10.1016/j.ebiom.2019.11.051
   PubMed Web of Science ®Google Scholar
• Yang HT, Xiu WJ, Liu JK, et al. Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia: probiotics increased. Bioengineered. 2021;12(1):7263–7275. doi:10.1080/21655979.2021.1976897
   PubMed Web of Science ®Google Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. doi:10.1038/nature11450
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhang J, Wang Z, et al. Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci Rep. 2016;6:20602. doi:10.1038/srep20602
   PubMed Web of Science ®Google Scholar
• Choi BG, Kim DJ, Baek MJ, et al. Hyperuricaemia and development of type 2 diabetes mellitus in Asian population. Clin Exp Pharmacol Physiol. 2018;45(6):499–506. doi:10.1111/1440-1681.12911
   PubMed Web of Science ®Google Scholar
• Su H, Liu T, Li Y, et al. Serum uric acid and its change with the risk of type 2 diabetes: a prospective study in China. Prim Care Diabetes. 2021;15(6):1002–1006. doi:10.1016/j.pcd.2021.06.010
   PubMed Web of Science ®Google Scholar
• Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol. 2012;176(2):108–116. doi:10.1093/aje/kws002
   PubMed Web of Science ®Google Scholar
• Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737–1742. doi:10.2337/dc09-0288
   PubMed Web of Science ®Google Scholar
• Zeng Y, Guo M, Fang X, et al. Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: a Systematic Review and Meta-Analysis. Adv Nutr. 2021;12(4):1286–1304. doi:10.1093/advances/nmab010
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413. doi:10.1681/ASN.2008010080
   PubMed Web of Science ®Google Scholar
• Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):27. doi:10.1186/s12882-016-0433-1
   PubMedGoogle Scholar
• Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104. doi:10.2337/dc11-1346
   PubMed Web of Science ®Google Scholar
• Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One. 2021;16(2):e0244689. doi:10.1371/journal.pone.0244689
   PubMed Web of Science ®Google Scholar
• Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384–1395. doi:10.1161/CIRCULATIONAHA.118.037778
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462. doi:10.1111/dom.13101
   PubMed Web of Science ®Google Scholar
• Hussain M, Elahi A, Hussain A, Iqbal J, Akhtar L, Majid A. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes. J Diabetes Res. 2021;2021:9973862. doi:10.1155/2021/9973862
   PubMed Web of Science ®Google Scholar
• Najafi S, Bahrami M, Butler AE, Sahebkar A. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(8):3627–3637. doi:10.1111/bcp.15344
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang H, Ke D, et al. Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study. Ther Adv Chronic Dis. 2021;12:20406223211026993. doi:10.1177/20406223211026993
   Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Chen R, Liu Y. Research progress on the relationship between intestinal flora and hyperuricemia and gout. J Nanjing Med University. 2020;40(10):1560–1564.
   Google Scholar
• Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats. Front Microbiol. 2018;9:2233. doi:10.3389/fmicb.2018.02233
   PubMed Web of Science ®Google Scholar
• Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671–682. doi:10.1038/s41575-018-0025-6
   PubMed Web of Science ®Google Scholar
• Wang Y, Dilidaxi D, Wu Y, Sailike J, Sun X, Nabi XH. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice. Biomed Pharmacother. 2020;125:109914. doi:10.1016/j.biopha.2020.109914
   PubMed Web of Science ®Google Scholar
• Wolter M, Grant ET, Boudaud M, et al. Leveraging diet to engineer the gut microbiome. Nat Rev Gastroenterol Hepatol. 2021;18(12):885–902. doi:10.1038/s41575-021-00512-7
   PubMed Web of Science ®Google Scholar
• Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510–1519. doi:10.1136/gutjnl-2019-320204
   PubMed Web of Science ®Google Scholar
• Ahlawat S. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol. 2021;72(6):636–668. doi:10.1111/lam.13333
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang Y, Zeng L, et al. The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease. Front Pharmacol. 2021;12:757508. doi:10.3389/fphar.2021.757508
   PubMed Web of Science ®Google Scholar
• Zixin Y, Lulu C, Xiangchang Z, et al. TMAO as a potential biomarker and therapeutic target for chronic kidney disease: a review. Front Pharmacol. 2022;13:929262. doi:10.3389/fphar.2022.929262
   PubMedGoogle Scholar
• Su HY, Yang C, Liang D, Liu HF. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. Biomed Res Int. 2020;2020:5817348. doi:10.1155/2020/5817348
   PubMed Web of Science ®Google Scholar
• Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol. 2005;147:132–148. doi:10.1159/000082551
   PubMed Web of Science ®Google Scholar
• Maejima I, Takahashi A, Omori H, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 2013;32(17):2336–2347. doi:10.1038/emboj.2013.171
   PubMed Web of Science ®Google Scholar
• Hasegawa J, Maejima I, Iwamoto R, Yoshimori T. Selective autophagy: lysophagy. Methods. 2015;75:128–132. doi:10.1016/j.ymeth.2014.12.014
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3(3):208–220. doi:10.1159/000355405
   PubMed Web of Science ®Google Scholar
• Stellato D, Morrone LF, Di Giorgio C, Gesualdo L. Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? Intern Emerg Med. 2012;7(1):5–8. doi:10.1007/s11739-011-0642-3
   PubMed Web of Science ®Google Scholar
• Cristobal-Garcia M, Garcia-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev. 2015;2015:535686. doi:10.1155/2015/535686
   PubMed Web of Science ®Google Scholar
• Song X, Sun Z, Chen G, et al. Matrix stiffening induces endothelial dysfunction via the TRPV4/microRNA-6740/endothelin-1 mechanotransduction pathway. Acta Biomater. 2019;100:52–60. doi:10.1016/j.actbio.2019.10.013
   PubMed Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–163. doi:10.1016/j.cca.2018.05.046
   PubMed Web of Science ®Google Scholar
• Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145–4151. doi:10.2174/138161205774913255
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–1293. doi:10.1161/01.HYP.0000072820.07472.3B
   PubMed Web of Science ®Google Scholar
• Rabadi MM, Kuo MC, Ghaly T, et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Renal Physiol. 2012;302(6):F730–41. doi:10.1152/ajprenal.00520.2011
   PubMed Web of Science ®Google Scholar
• Choe JY, Choi CH, Park KY, Kim SK. High-mobility group box 1 is responsible for monosodium urate crystal-induced inflammation in human U937 macrophages. Biochem Biophys Res Commun. 2018;503(4):3248–3255. doi:10.1016/j.bbrc.2018.08.139
   PubMed Web of Science ®Google Scholar
• Cai W, Duan XM, Liu Y, et al. Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway. Biomed Res Int. 2017;2017:4391920. doi:10.1155/2017/4391920
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–1742. doi:10.1111/j.1523-1755.2005.00273.x
   PubMed Web of Science ®Google Scholar
• Shi L, Wang Q, Zhang L. Effects of hyperuricemia on early diabetic nephropathy in elderly patients. Chine J Gerontol. 2009;29(22):2862–2864.
   Google Scholar
• Chen X, Luo S, Liao S. Study on the relationship between reduced glucose tolerance and blood lipid and uric acid levels. Chine J Med Med. 2006;8(005):696–697.
   Google Scholar
• Mauer M, Doria A. Uric acid and risk of diabetic kidney disease. J Nephrol. 2020;33(5):995–999. doi:10.1007/s40620-020-00796-z
   PubMed Web of Science ®Google Scholar
• Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. doi:10.1080/19490976.2015.1134082
   PubMed Web of Science ®Google Scholar
• He J, Zhang P, Shen L, et al. Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism. Int J Mol Sci. 2020;21(17). doi:10.3390/ijms21176356
   Web of Science ®Google Scholar
• Croci S, D’Apolito LI, Gasperi V, Catani MV, Savini I. Dietary Strategies for Management of Metabolic Syndrome: role of Gut Microbiota Metabolites. Nutrients. 2021;13(5). doi:10.3390/nu13051389
   PubMed Web of Science ®Google Scholar
• Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021;20:301–319. doi:10.17179/excli2020-3239
   PubMed Web of Science ®Google Scholar
• Cho CE, Caudill MA. Trimethylamine-N-Oxide: friend, Foe, or Simply Caught in the Cross-Fire? Trends Endocrinol Metab. 2017;28(2):121–130. doi:10.1016/j.tem.2016.10.005
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. doi:10.1161/CIRCRESAHA.116.305360
   PubMed Web of Science ®Google Scholar
• Sun G, Yin Z, Liu N, et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem Biophys Res Commun. 2017;493(2):964–970. doi:10.1016/j.bbrc.2017.09.108
   PubMed Web of Science ®Google Scholar
• Li T, Gua C, Wu B, Chen Y. Increased circulating trimethylamine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Biochem Biophys Res Commun. 2018;495(2):2071–2077. doi:10.1016/j.bbrc.2017.12.069
   PubMed Web of Science ®Google Scholar
• Fang Q, Zheng B, Liu N, et al. Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease. Front Physiol. 2021;12:682482. doi:10.3389/fphys.2021.682482
   PubMed Web of Science ®Google Scholar
• Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway. J Am Heart Assoc. 2017;6(9). doi:10.1161/JAHA.117.006347
   Web of Science ®Google Scholar
• Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022;127:154937. doi:10.1016/j.metabol.2021.154937.
   Google Scholar
• Garla VV, Butler J, Lien LF. SGLT-2 Inhibitors in heart failure: guide for prescribing and future perspectives. Curr Cardiol Rep. 2021;23(6):59. doi:10.1007/s11886-021-01486-3
   PubMed Web of Science ®Google Scholar
• Grubic Rotkvic P, Cigrovski Berkovic M, Bulj N, Rotkvic L, Celap I. Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure. World J Diabetes. 2020;11(7):269–279. doi:10.4239/wjd.v11.i7.269
   PubMed Web of Science ®Google Scholar
• Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol. 2019;316(1):F173–F85. doi:10.1152/ajprenal.00462.2018
   PubMed Web of Science ®Google Scholar
• Ahmed MI, Gladden JD, Litovsky SH, et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol. 2010;55(7):671–679. doi:10.1016/j.jacc.2009.08.074
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854. doi:10.1016/S2213-8587(19)30256-6
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350. doi:10.1161/CIRCULATIONAHA.107.739938
   PubMed Web of Science ®Google Scholar
• Verge D, Lopez X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev. 2010;6(4):191–200. doi:10.2174/157339910791658853
   PubMedGoogle Scholar
• Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 2017;43(Suppl 1):2S20–2S7. doi:10.1016/S1262-3636(17)30069-1
   PubMedGoogle Scholar
• Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014;10(2):77–87. doi:10.1038/nrneph.2013.251
   PubMed Web of Science ®Google Scholar
• Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Medicina. 2019;55(6). doi:10.3390/medicina55060233
   Google Scholar
• Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–486. doi:10.1016/j.beem.2009.03.004
   PubMed Web of Science ®Google Scholar
• Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017;59(1):R1–R10. doi:10.1530/JME-17-0005
   PubMed Web of Science ®Google Scholar
• von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54–60. doi:10.1097/01.mnh.0000437542.77175.a0
   PubMed Web of Science ®Google Scholar
• Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–628. doi:10.1038/nrneph.2017.123
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014;11(5):306–323. doi:10.1177/1479164114542802
   PubMed Web of Science ®Google Scholar
• Hasan AA, von Websky K, Reichetzeder C, et al. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy. Kidney Int. 2019;95(6):1373–1388. doi:10.1016/j.kint.2019.01.010
   PubMed Web of Science ®Google Scholar
• Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414(1):1–18. doi:10.1042/BJ20080595
   PubMedGoogle Scholar
• Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. Pharmacol Res. 2021;172:105859. doi:10.1016/j.phrs.2021.105859
   PubMed Web of Science ®Google Scholar